Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor’s poster presentation will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For more information on the 2015 Lancet Viral Hepatitis Meeting: www.asianoncologysummit.com/vhep-summit.asp
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.
Website: http://www.replicor.com
Contact
Replicor
Alexandra Peterson
212-508-9709
apeterson@makovsky.com
This news is a press release provided by Replicor Inc..
-
2017년 9월 28일 22:05